Implications of Neuroendocrine Tumor and Diabetes Mellitus on Patient Outcomes and Care: a Matched case–control Study

Kusne, Yael; Kosiorek, Heidi E.; Buras, Matthew R.; Verona, Patricia M; Coppola, Kyle; Rone, Kelley; Cook, Curtiss B.; Karlin, Nina J.

doi:10.2144/fsoa-2020-0190

Cited by 6 publications

(5 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In their case-control study, diabetes had no negative impact on the survival of patients with neuroendocrine tumors [41]. Similarly, Pusceddu et al have not recognized diabetes as a negative prognostic factor [39].…”

Section: Discussionmentioning

confidence: 88%

“…Tan et al reported that preoperative new-onset diabetes and impaired fasting glucose (IFG) are correlated with aggressive tumor behavior and poor recurrence-free survival (RFS) of patients with non-functional PanNENs [ 40 ]. Different conclusions were drawn from study by Kusne et al In their case–control study, diabetes had no negative impact on the survival of patients with neuroendocrine tumors [ 41 ]. Similarly, Pusceddu et al have not recognized diabetes as a negative prognostic factor [ 39 ].…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Assessment of the Role of Leptin and Adiponectinas Biomarkers in Pancreatic Neuroendocrine Neoplasms

Bocian-Jastrzębska,

Malczewska-Herman,

Rosiek

et al. 2023

Cancers

View full text Add to dashboard Cite

Data on the possible connection between circulating adipokines and PanNENs are limited. This novel study aimed to assess the serum levels of leptin and adiponectin and their ratio in patients with PanNENs and to evaluate the possible relationship between them and PanNEN’s grade or stage, including the presence of metastases. The study group consisted of PanNENs (n = 83), and healthy controls (n = 39). Leptin and adiponectin measurement by an ELISA assay was undertaken in the entire cohort. The serum concentration of adiponectin was significantly higher in the control group compared to the study group (p < 0.001). The concentration of leptin and adiponectin was significantly higher in females than in males (p < 0.01). Anincreased leptin–adiponectin ratio was observed in well-differentiated PanNENs (G1) vs. moderatelydifferentiated PanNENs (G2) (p < 0.05). An increased leptin–adiponectin ratio was found in PanNENs with Ki-67 < 3% vs. Ki-67 ≥ 3% (p < 0.05). PanNENs with distal disease presented lower leptin levels (p < 0.001) and a decreased leptin–adiponectin ratio (p < 0.01) compared with the localized disease group. Leptin, adiponectin, and the leptin–adiponectin ratio may serve as potential diagnostic, prognostic, and predictive biomarkers for PanNENs. Leptin levels and the leptin–adiponectin ratio may play an important role as predictors of malignancy and metastasis in PanNENs.

show abstract

Section: Discussionmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 92%

Assessment of the Role of Leptin and Adiponectinas Biomarkers in Pancreatic Neuroendocrine Neoplasms

Bocian-Jastrzębska,

Malczewska-Herman,

Rosiek

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…However, for more advanced diseases, biotherapy using somatostatin analogs may be used [18]. Somatostatin analogs may inhibit the secretion of insulin and glucagon, thus impacting glycemic balance [3]. Everolimus has also been used as a therapeutic agent both alone and in combination with the somatostatin analog, octreotide, and has been associated with hyperglycemia [19].…”

Section: Discussionmentioning

confidence: 99%

“…Carcinoid tumors themselves, as well as certain existing treatments, can impact the management of other conditions, such as diabetes, by impacting glycemic control and balance [2]. Given that the incidences of neuroendocrine tumors, diabetes, and hypertension are rising [3,4], better elucidating the impact of carcinoid tumors and their treatments on such conditions, as well as formally establishing treatment protocols to optimize patient counseling is important. Patients also should be regularly counseled on screening recommendations that may enable earlier diagnosis.…”

Section: Introductionmentioning

confidence: 99%

Incidentally Found Rectal Carcinoid Tumor in a 46-Year-Old Female: The Potential for Complications and the Importance of Screening Guidelines

Lapides,

Shah,

Bal

2024

Cureus

View full text Add to dashboard Cite

Carcinoid tumors are rare neuroendocrine tumors that can be found in the gastrointestinal tract as well as other areas throughout the body. The neurosecretory nature of these tumors can have implications for other chronic diseases that patients may have, such as diabetes. Certain treatments that may be implemented for patients who have carcinoid tumors, such as somatostatin analogs and Everolimus, can also alter blood glucose control. This highlights the importance of diagnosing and treating carcinoid tumors as early as possible to avoid complications associated with metastasis and more intense treatment. With more advanced diseases, clinicians should consider the possible effects of carcinoid tumors and their treatments on other chronic conditions as they manage the patient. For gastrointestinal carcinoid tumors, colonoscopy screening guidelines are incredibly important to counsel patients on, as resection can yield a complete cure for carcinoid tumors when they are found at an early stage. Here, we describe the case of an incidentally diagnosed rectal carcinoid tumor in a 46-year-old female patient with a history of type 2 diabetes mellitus and hypertension.

show abstract

“…The use of therapies for NENs, such as somatostatin analogues (SSAs) and mTOR inhibitors, can also cause impaired glucose metabolism and insulin resistance [100]. Diabetes is an established risk factor for NENs, although most evidence suggests that patients with NENs and diabetes generally do not differ significantly in their outcomes in comparison to non-diabetic patients [100,101]. However, some studies have suggested that diabetes can modify the risk of metastases.…”

Section: Diabetes Obesity and Nensmentioning

confidence: 99%

Exploring the Relationship between Obesity, Metabolic Syndrome and Neuroendocrine Neoplasms

2022

View full text Add to dashboard Cite

Obesity is a major burden for modern medicine, with many links to negative health outcomes, including the increased incidence of certain cancer types. Interestingly, some studies have supported the concept of an “Obesity Paradox”, where some cancer patients living with obesity have been shown to have a better prognosis than non-obese patients. Neuroendocrine neoplasms (NENs) are malignancies originating from neuroendocrine cells, in some cases retaining important functional properties with consequences for metabolism and nutritional status. In this review, we summarize the existing evidence demonstrating that obesity is both a risk factor for developing NENs as well as a good prognostic factor. We further identify the limitations of existing studies and further avenues of research that will be necessary to optimize the metabolic and nutritional status of patients living with NENs to ensure improved outcomes.

show abstract

Implications of Neuroendocrine Tumor and Diabetes Mellitus on Patient Outcomes and Care: a Matched case–control Study

Cited by 6 publications

References 37 publications

Assessment of the Role of Leptin and Adiponectinas Biomarkers in Pancreatic Neuroendocrine Neoplasms

Assessment of the Role of Leptin and Adiponectinas Biomarkers in Pancreatic Neuroendocrine Neoplasms

Incidentally Found Rectal Carcinoid Tumor in a 46-Year-Old Female: The Potential for Complications and the Importance of Screening Guidelines

Exploring the Relationship between Obesity, Metabolic Syndrome and Neuroendocrine Neoplasms

Contact Info

Product

Resources

About